E-mail

E-mail a Wiley Online Library Link

Andrew J. Weickhardt, Robert C. Doebele, W. Thomas Purcell, Paul A. Bunn, Ana B. Oton, Micol S. Rothman, Margaret E. Wierman, Tony Mok, Sanjay Popat, Julie Bauman, Jorge Nieva, Silvia Novello, Sai-Hong Ignatius Ou and D. Ross Camidge Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients Cancer 119

Version of Record online: 12 APR 2013 | DOI: 10.1002/cncr.28089

Crizotinib therapy rapidly reduced total testosterone levels in 84% of men studied (27 of 32), reflecting decreases in both gonadotropins and in testosterone-binding proteins. Free testosterone was low in 76%, with the majority (84%) manifesting symptoms of androgen deficiency and more than half experiencing benefit from testosterone replacement.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH